10:50 AM EST, 01/07/2025 (MT Newswires) -- Immunome ( IMNM ) received a worldwide license from Hummingbird Bioscience to monoclonal antibodies for a single undisclosed target, the biotherapeutics company said Tuesday.

Hummingbird said it will receive an upfront payment and is eligible for future development and commercial milestone payments and royalties.

Financial terms were not disclosed.

Immune will carry out research, development, manufacturing and commercialization of products incorporating these antibodies, according to Hummingbird.

Price: 11.12, Change: -0.08, Percent Change: -0.71